American International Group Inc. Sells 1,032 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

American International Group Inc. lessened its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 0.8% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 132,511 shares of the company’s stock after selling 1,032 shares during the period. American International Group Inc. owned approximately 0.13% of Neurocrine Biosciences worth $18,276,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Mather Group LLC. purchased a new stake in Neurocrine Biosciences during the first quarter valued at approximately $26,000. RFP Financial Group LLC grew its holdings in Neurocrine Biosciences by 346.5% during the 1st quarter. RFP Financial Group LLC now owns 192 shares of the company’s stock valued at $26,000 after buying an additional 149 shares in the last quarter. Lindbrook Capital LLC raised its holdings in shares of Neurocrine Biosciences by 85.0% during the 4th quarter. Lindbrook Capital LLC now owns 209 shares of the company’s stock worth $28,000 after acquiring an additional 96 shares in the last quarter. EdgeRock Capital LLC bought a new stake in shares of Neurocrine Biosciences in the 4th quarter worth about $31,000. Finally, Benjamin F. Edwards & Company Inc. bought a new position in shares of Neurocrine Biosciences in the 4th quarter valued at about $33,000. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Neurocrine Biosciences

In other news, insider Ingrid Delaet sold 273 shares of the business’s stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $140.55, for a total transaction of $38,370.15. Following the transaction, the insider now owns 7,507 shares of the company’s stock, valued at approximately $1,055,108.85. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other Neurocrine Biosciences news, Director Gary A. Lyons sold 12,500 shares of the firm’s stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $135.63, for a total transaction of $1,695,375.00. Following the completion of the sale, the director now owns 116,947 shares of the company’s stock, valued at $15,861,521.61. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Ingrid Delaet sold 273 shares of the company’s stock in a transaction on Monday, May 6th. The shares were sold at an average price of $140.55, for a total value of $38,370.15. Following the completion of the transaction, the insider now directly owns 7,507 shares in the company, valued at approximately $1,055,108.85. The disclosure for this sale can be found here. Insiders sold a total of 80,709 shares of company stock worth $11,009,150 in the last three months. 4.30% of the stock is owned by corporate insiders.

Neurocrine Biosciences Stock Up 0.3 %

Shares of NASDAQ NBIX traded up $0.44 during trading on Wednesday, hitting $145.88. The company had a trading volume of 623,554 shares, compared to its average volume of 810,617. The stock has a fifty day simple moving average of $138.99 and a two-hundred day simple moving average of $137.75. Neurocrine Biosciences, Inc. has a fifty-two week low of $99.10 and a fifty-two week high of $150.39. The firm has a market capitalization of $14.68 billion, a price-to-earnings ratio of 40.19 and a beta of 0.37.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Wednesday, May 1st. The company reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.04 by ($0.62). Neurocrine Biosciences had a return on equity of 17.45% and a net margin of 18.65%. The business had revenue of $515.30 million for the quarter, compared to analyst estimates of $512.21 million. On average, analysts anticipate that Neurocrine Biosciences, Inc. will post 4.2 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Oppenheimer increased their target price on shares of Neurocrine Biosciences from $200.00 to $216.00 and gave the company an “outperform” rating in a research note on Thursday, May 2nd. Needham & Company LLC restated a “hold” rating on shares of Neurocrine Biosciences in a report on Wednesday, May 1st. JPMorgan Chase & Co. boosted their price target on Neurocrine Biosciences from $169.00 to $173.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 10th. Cantor Fitzgerald reiterated an “overweight” rating and set a $155.00 price objective on shares of Neurocrine Biosciences in a research note on Wednesday, April 10th. Finally, Morgan Stanley raised their price objective on Neurocrine Biosciences from $160.00 to $170.00 and gave the stock an “overweight” rating in a research report on Friday, July 12th. Six analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $152.96.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.